Atorvastatin hemicalcium trihydrate

Cat. No.: HY-B0589E: FAQs
Data Sheet Handling Instructions

Molarity Calculator

Atorvastatin hemicalcium trihydrate is an orally active HMG-CoA reductase inhibitor, has the ability to effectively decrease blood lipids. Atorvastatin hemicalcium trihydrate inhibits human SV-SMC proliferation and invasion with IC₅₀s of 0.39 μM and 2.39 μM, respectively.

For research use only. We do not sell to patients.

Atorvastatin hemicalcium trihydrate Chemical Structure

CAS No. : 344920-08-7

Size		Stock
MOQ		Minimum order quantity
50 mg		Get quote
100 mg		Get quote
250 mg		Get quote
Other size		Get quote

Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other In-stock Forms of Atorvastatin hemicalcium trihydrate:

Atorvastatin hemicalcium salt

Other Forms of Atorvastatin hemicalcium trihydrate:

38 Publications Citing Use of MCE Atorvastatin hemicalcium trihydrate

Proliferation Assay

: Atorvastatin hemicalcium trihydrate purchased from MedChemExpress. Usage Cited in: Oncogene. 2022 Oct 31. [Abstract]; ATP assay. The combination of Atorvastatin (2.5, 5, 10, 20 μM; 48 h) and SR1078 synergistically inhibits CRC cell viability.

: Atorvastatin hemicalcium trihydrate purchased from MedChemExpress. Usage Cited in: Endocrinology. 2018 May 1;159(5):2008-2021. [Abstract]; Male C57BL/6 mice are intragastrically treated with Atorvastatin (0.1 mg/kg/day) and placebo for 10 weeks in the presence of HFD after 10-week-HFD feeding and then sacrificed for sample collection. H&E and oil red O staining of frozen liver sections.

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

In Vitro

Atorvastatin hemicalcium trihydrate treatment decreases apoptosis of myocardial cells by down-regulating GRP78, caspase-12 and CHOP expression in myocardial cells after myocardial infarction, and the endoplasmic reticulum (ER) stress is activated in response to heart failure and angiotensin II (Ang II) stimulation^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Atorvastatin (20-30 mg/kg; oral gavage; once a day; for 28 days; ApoE^?/? mice) hemicalcium trihydrate treatment significantly reduces endoplasmic reticulum (ER) stress signaling proteins, the number of apoptotic cells, and the activation of Caspase12 and Bax in the Ang II-induced ApoE-/- mice. Proinflammatory cytokines such as IL-6, IL-8, IL-1β are all remarkably inhibited after Atorvastatin treatment^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Forty 8-week-old ApoE^−/− mice induced with angiotensin II (Ang II)^[5]
Dosage:	20 mg/kg, 30 mg/kg
Administration:	Oral gavage; once a day; for 28 days
Result:	Significantly reduced ER stress signaling proteins, the number of apoptotic cells, and the activation of Caspase12 and Bax in the Ang II-induced ApoE^−/− mice. Proinflammatory cytokines such as IL-6, IL-8, IL-1β were all remarkably inhibited.

Clinical Trial

Molecular Weight

632.73

Formula

C₃₃H₃₅FN₂O₅.1/2Ca.3H₂O

CAS No.

344920-08-7

SMILES

O=C(C(C(C1=CC=CC=C1)=C(C2=CC=C(F)C=C2)N3CC[C@@H](O)C[C@@H](O)CC(O)=O)=C3C(C)C)NC4=CC=CC=C4.[1/2].[Ca].O.O.O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Santodomingo-Garzón T, et al. Atorvastatin inhibits inflammatory hypernociception. Br J Pharmacol. 2006 Sep;149(1):14-22. [Content Brief]

[2]. Turner NA, et al. Comparison of the efficacies of five different statins on inhibition of human saphenous vein smooth muscle cell proliferation and invasion. J Cardiovasc Pharmacol. 2007 Oct;50(4):458-61. [Content Brief]

[3]. Nawrocki, J.W., et al., Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol, 1995. 15(5): p. 678-82. [Content Brief]

[4]. Song XJ, et al. Atorvastatin inhibits myocardial cell apoptosis in a rat model with post-myocardial infarction heart failure by downregulating ER stress response. Int J Med Sci. 2011;8(7):564-72. [Content Brief]

[5]. Li Y, et al. Inhibition of endoplasmic reticulum stress signaling pathway: A new mechanism of statins to suppress the development of abdominal aortic aneurysm. PLoS One. 2017 Apr 3;12(4):e0174821. [Content Brief]